… revealed superior PFS with osimertinib compared with first-generation EGFR TKIs (erlotinib
or gefitinib), and osimertinib has become the preferred first-line therapy. Consequently, there …

… Our purpose of this study is to investigate how afatinib is used in real-world practice, and
whether it leads to different clinical outcomes compared with gefitinib or erlotinib. …

… randomized controlled trial to directly compare lower dose erlotinib with standard dose gefitinib
… Therefore, in Stage IV EGFR mutated NSCLC, this study showed that erlotinib 100 mg/d …

… now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus
erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. …

… (gefitinib and erlotinib) as a result of acquired drug resistance and relapse.7 Combination
treatments with EGFR TKIs is one strategy to overcome acquired resistance and to improve …

… The current study examines the efficacy, safety, and tolerability of ASP8273 versus
erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR …

… gefitinib or erlotinib in patients with the L858R. The RELAY … aware, our study is the first phase
III clinical trial to target only … the present study is achieved, the combination of erlotinib plus …

… inhibitors (TKIs), erlotinib and gefitinib, the second-generation … EGFR TKIs are being
evaluated in multiple clinical trials. … erlotinib treated EGFR mutant patients [15,19]. In the present …

… ) trial showed the superiority of adjuvant gefitinib over … open-label, phase II, randomized
controlled trial of erlotinib versus GC … All patients were randomly assigned 1:1 to receive erlotinib …

… Gefitinib, erlotinib, and afatinib have comparable efficacies in terms of objective response …
-generation oral TKIs for T790M mutation; clinical trials if MET amplification, PIK3CA, BRAF, or …